🔷 Temperature

🔷 Initially, the client had warm and moist skin, which is commonly associated with hyperthyroidism due to increased metabolic activity and heat production.

🔷 At the follow-up visit, the skin is described as warm and dry, indicating improvement in excessive metabolic stimulation.

🔷 Improvement in temperature regulation suggests that the prescribed treatment is helping control the overactive thyroid state.

🔷 Reduced heat intolerance is an important sign that the client’s condition is stabilizing.

💎 Weight

💎 The client originally reported weight loss despite increased appetite, which is a classic manifestation of hyperthyroidism because metabolism is excessively increased.

💎 Improvement in the condition would be reflected by stabilization or improvement in weight status.

💎 As thyroid hormone levels become controlled, the body’s metabolic rate decreases toward normal.

💎 This allows the client to regain or maintain weight more appropriately.

🌿 Heart rate

🌿 Hyperthyroidism commonly causes tachycardia because excess thyroid hormone stimulates the cardiovascular system.

🌿 Improvement in thyroid function is associated with a reduction in heart rate toward normal levels.

🌿 Improved cardiovascular stability is an important indicator that treatment is effective.

🌿 Nurses should continue monitoring pulse rate and signs of palpitations or dysrhythmias.

⚡ Sleep pattern

⚡ The client originally reported insomnia, which is common in hyperthyroidism due to nervous system overstimulation.

⚡ At the follow-up visit, the client reports that insomnia has improved, indicating a positive treatment response.

⚡ Improved sleep suggests decreased metabolic and neurologic hyperactivity.

⚡ Better rest can also improve energy balance, mood, and overall recovery.

❌ Mood

❌ The client still reports feeling anxious, indicating this symptom has not fully improved.

❌ Persistent anxiety suggests the condition may still require further management or adjustment of therapy.

❌ Abdominal findings

❌ The abdomen was soft, non-tender, and had normoactive bowel sounds both initially and at follow-up.

❌ Since there was no abnormality initially, this does not specifically indicate improvement.

✅ Fatigue

🔷 Fatigue and weakness are common early manifestations of digoxin toxicity due to its effects on cardiac conduction and decreased cardiac output.

✅ Nausea

🔷 Gastrointestinal symptoms such as nausea are classic signs of digoxin toxicity and often occur early before severe cardiac complications develop.

✅ Blurred vision

🔷 Visual disturbances such as blurred vision, yellow vision, or seeing halos are hallmark signs of digoxin toxicity.

✅ Digoxin 2.2 ng/mL

🔷 The therapeutic digoxin level is approximately 0.8–2 ng/mL.

🔷 A level of 2.2 ng/mL is elevated and supports digoxin toxicity.

✅ Heart rate 55/min

🔷 Digoxin toxicity can cause bradycardia and conduction abnormalities.

🔷 A heart rate of 55/min is concerning in a client taking digoxin.

Do not highlight:

❌ Improvement in shortness of breath with exertion — indicates improving heart failure symptoms.

❌ S3 heart sound — associated with heart failure, not specifically toxicity.

❌ Lung sounds clear — improvement, not toxicity.

❌ 1+ edema on ankles — improved from previous 2+ edema.

❌ Potassium 4.8 mEq/L — within normal range.

❌ Temperature, respiratory rate, blood pressure, oxygen saturation — not indicating toxicity here.

🔷 Blank 1: Muscle rigidity

🔷 The nurse should address muscle rigidity first because the client received succinylcholine and isoflurane, which are classic triggering medications for malignant hyperthermia.

🔷 Muscle rigidity, especially generalized rigidity or jaw rigidity, is often one of the earliest warning signs of malignant hyperthermia.

🔷 Malignant hyperthermia is a life-threatening hypermetabolic reaction in skeletal muscle that can rapidly progress to severe complications.

🔷 When rigidity appears after exposure to these anesthetic agents, the nurse should suspect an emergency and act quickly.

🔷 Immediate actions include notifying the anesthesia provider/surgeon, stopping triggering agents, administering dantrolene, giving 100% oxygen, and preparing cooling measures.

💎 Blank 2: Heart rate

💎 The next priority finding is heart rate because malignant hyperthermia commonly causes tachycardia early as the body enters a severe hypermetabolic state.

💎 As skeletal muscles become overactive, the body consumes large amounts of oxygen and produces excess carbon dioxide, causing sympathetic stimulation.

💎 This can lead to a rapid increase in heart rate and may progress to dysrhythmias, especially if acidosis or hyperkalemia develops.

💎 Monitoring heart rate is critical because cardiovascular instability can occur quickly.

💎 A sudden unexplained increase in heart rate after anesthesia should always raise concern for malignant hyperthermia.

🌡️ Blank 3: Temperature

🌡️ Temperature is a major finding because malignant hyperthermia causes a rapid and dangerous rise in body temperature.

🌡️ Hyperthermia occurs from excessive skeletal muscle metabolism, which produces large amounts of heat.

🌡️ Although fever may be a later sign than muscle rigidity and tachycardia, it is a serious indicator that the condition is worsening.

🌡️ The nurse should monitor temperature closely and assist with cooling interventions such as cooling blankets, chilled IV fluids, ice packs, and lavage if ordered.

🌡️ Untreated malignant hyperthermia can lead to rhabdomyolysis, kidney injury, acidosis, hyperkalemia, cardiac arrest, and death.

❌ Lung sounds

❌ Lung sounds are important after anesthesia, but they are not the first finding that points to malignant hyperthermia.

❌ This emergency is primarily recognized by muscle rigidity, tachycardia, increased carbon dioxide, and rising temperature.

❌ Oxygen saturation

❌ Oxygen saturation should be monitored in the PACU, but it may remain normal early if the client is receiving oxygen.

❌ It is not as specific to malignant hyperthermia as muscle rigidity, heart rate changes, and temperature elevation.

❌ Mottling

❌ Mottling indicates poor perfusion or circulatory compromise, but it is not a classic early sign of malignant hyperthermia.

❌ If present, it would suggest worsening instability rather than the key priority recognition finding.

❌ Bowel sounds

❌ Bowel sounds are not relevant to identifying malignant hyperthermia.

❌ The emergency involves skeletal muscle metabolism, not gastrointestinal motility.

❌ Respiratory rate

❌ Respiratory rate may increase as the client develops acidosis and carbon dioxide retention.

❌ However, in this option set, heart rate and temperature are stronger hallmark findings after muscle rigidity.

❌ Nausea

❌ Nausea is common after anesthesia and does not indicate malignant hyperthermia.

❌ It is much less urgent than rigidity, tachycardia, and hyperthermia.

🔷 Losartan is an angiotensin II receptor blocker (ARB) used for clients with hypertension and diabetic nephropathy.

🔷 ARBs help slow kidney damage by decreasing pressure inside the glomeruli and reducing protein loss in the urine.

🔷 In diabetic nephropathy, protecting kidney function is a priority because long-term high blood glucose and hypertension can progressively damage renal blood vessels.

🔷 Losartan also helps control blood pressure, which further reduces stress on the kidneys.

🔷 The nurse should monitor blood pressure, potassium level, creatinine, and kidney function during therapy.

❌ Sitagliptin

❌ Sitagliptin helps improve blood glucose control in type 2 diabetes.

❌ It does not primarily slow diabetic nephropathy progression.

❌ Glipizide

❌ Glipizide is a sulfonylurea that lowers blood glucose by increasing insulin release.

❌ It does not provide the same kidney-protective effect as an ARB.

❌ Metoprolol

❌ Metoprolol lowers blood pressure and heart rate as a beta blocker.

❌ It is not the preferred kidney-protective medication for diabetic nephropathy.

💎 Ipratropium is an anticholinergic bronchodilator related pharmacologically to atropine.

💎 A client with an atropine allergy may be at risk for a hypersensitivity reaction to ipratropium, so this statement must be reported to the provider before use.

💎 Ipratropium helps open the airways by blocking muscarinic receptors, which reduces bronchoconstriction and mucus secretion.

💎 Serious allergy symptoms may include rash, swelling, bronchospasm, difficulty breathing, or anaphylaxis.

💎 The nurse should hold the medication and notify the provider for further instructions.

❌ “I hope this new medication won’t make my high blood pressure worse.”

❌ Ipratropium is not a stimulant bronchodilator and is less likely to worsen hypertension compared with some beta-agonists.

❌ This concern should be addressed with teaching, but it is not the priority reportable statement.

❌ “I want to keep using my albuterol when I feel like I need it.”

❌ Albuterol is often used as a rescue bronchodilator for acute bronchospasm.

❌ This statement may be appropriate depending on the prescription and does not require immediate provider notification.

❌ “I usually have a glass of red wine with dinner.”

❌ Moderate alcohol use is not a specific contraindication to ipratropium.

❌ This does not create the same safety concern as an atropine allergy.

🔷 Raloxifene is a selective estrogen receptor modulator used to prevent and treat osteoporosis in postmenopausal clients.

🔷 The nurse should assess pregnancy status before therapy because raloxifene is contraindicated during pregnancy and can harm a developing fetus.

🔷 Although osteoporosis therapy is usually for postmenopausal clients, pregnancy must still be ruled out when applicable.

🔷 The nurse should also teach that raloxifene increases the risk for venous thromboembolism, so calf pain, swelling, chest pain, or sudden shortness of breath must be reported.

❌ CBC results

❌ CBC results are not the priority assessment before starting raloxifene.

❌ The major safety concerns are pregnancy and thromboembolism risk.

❌ Family history of colon cancer

❌ Raloxifene is not primarily screened around colon cancer history.

❌ This does not determine whether raloxifene can be safely started.

❌ Thyroid function

❌ Thyroid function is not the priority baseline assessment for raloxifene therapy.

❌ Thyroid disorders can affect bone health, but this is not the key contraindication.

💎 Sumatriptan is a triptan medication used for acute migraine treatment.

💎 It works by stimulating serotonin receptors, causing cranial blood vessel constriction and reducing migraine symptoms.

💎 Because it causes vasoconstriction, it is contraindicated in clients with coronary artery disease, history of myocardial infarction, uncontrolled hypertension, stroke, or significant vascular disease.

💎 In a client with CAD, sumatriptan can worsen cardiac ischemia and increase the risk for chest pain, dysrhythmias, or myocardial infarction.

💎 The nurse should report this history to the provider and anticipate a safer migraine treatment option.

❌ Asthma

❌ Asthma is not a major contraindication to sumatriptan.

❌ The main concern is vascular disease because of vasoconstriction.

❌ Kidney disease

❌ Kidney disease may require medication review, but it is not the classic contraindication for sumatriptan.

❌ Cardiovascular disease is the priority concern.

❌ Rheumatoid arthritis

❌ Rheumatoid arthritis does not contraindicate sumatriptan.

❌ It does not create the same vasoconstriction risk as CAD.

🌿 Pramlintide is an amylin analog used with mealtime insulin in clients with type 1 or type 2 diabetes.

🌿 It slows gastric emptying, suppresses glucagon secretion, and promotes satiety, which helps reduce post-meal glucose elevations.

🌿 When used with insulin, especially rapid-acting insulin such as lispro, pramlintide can increase the risk for severe hypoglycemia, especially within the first 3 hours after administration.

🌿 The nurse should monitor blood glucose closely and ensure the client understands symptoms of hypoglycemia such as sweating, shakiness, confusion, hunger, palpitations, and weakness.

🌿 Pramlintide is given immediately before major meals and should be injected separately from insulin.

❌ Monitor the client for weight gain.

❌ Pramlintide commonly causes decreased appetite and may lead to weight loss, not weight gain.

❌ Monitoring weight is useful, but weight gain is not the expected concern.

❌ Inject the pramlintide in the client’s upper arm.

❌ Pramlintide is usually injected subcutaneously in the abdomen or thigh.

❌ It should not be mixed with insulin and should be administered as a separate injection.

❌ Administer pramlintide 30 min prior to a meal.

❌ Pramlintide should be administered immediately before meals, not 30 minutes before.

❌ Giving it too early can increase hypoglycemia risk.

🔷 Gentamicin is an aminoglycoside antibiotic that can cause nephrotoxicity (kidney damage) and ototoxicity as serious adverse effects.

🔷 The nurse should closely monitor the client’s creatinine level because elevated creatinine may indicate worsening kidney function caused by the medication.

🔷 Aminoglycosides can damage the renal tubules, especially with prolonged therapy, high doses, dehydration, older age, or preexisting kidney disease.

🔷 Signs of nephrotoxicity may include rising creatinine and BUN levels, decreased urine output, fluid retention, and electrolyte abnormalities.

🔷 The nurse should also monitor intake and output, hydration status, medication peak and trough levels if ordered, and assess for hearing changes or tinnitus.

🔷 Early recognition of kidney injury is important because nephrotoxicity may become severe or irreversible if not addressed promptly.

❌ B-type natriuretic peptide (BNP)

❌ BNP is primarily used to evaluate and monitor heart failure.

❌ It does not assess for gentamicin toxicity.

❌ Amylase level

❌ Amylase is commonly used to evaluate pancreatic disorders such as pancreatitis.

❌ It is not used to monitor the adverse effects of gentamicin.

❌ Erythrocyte sedimentation rate (ESR)

❌ ESR is a nonspecific marker of inflammation.

❌ It does not detect kidney toxicity caused by aminoglycosides.

🔷 Beclomethasone is an inhaled corticosteroid (ICS) used for the long-term control and prevention of asthma inflammation.

🔷 Inhaled corticosteroids can leave medication residue in the mouth and throat, increasing the risk for oral candidiasis (thrush) and hoarseness.

🔷 Gargling and rinsing the mouth with water after each use helps remove residual medication and reduces the risk of fungal infection and irritation.

🔷 The client should spit out the water after rinsing rather than swallow it.

🔷 Beclomethasone is not a rescue medication; it works gradually to decrease airway inflammation and prevent asthma exacerbations over time.

🔷 Proper inhaler technique and consistent daily use are important for effective asthma control.

❌ “There is no need to use a spacer for this inhaler.”

❌ A spacer is often recommended with metered-dose corticosteroid inhalers because it improves medication delivery to the lungs.

❌ Spacers also decrease medication deposition in the mouth and reduce the risk of thrush.

❌ “You should use this inhaler for any acute incidents of shortness of breath.”

❌ Beclomethasone is not a rescue inhaler and does not provide rapid bronchodilation.

❌ Acute asthma symptoms should be treated with a short-acting bronchodilator such as albuterol.

❌ “Use the beclomethasone inhaler before using your albuterol inhaler to increase absorption.”

❌ The correct sequence is to use albuterol first because it opens the airways.

❌ Once the bronchi are dilated, the corticosteroid can penetrate the lungs more effectively.